Pharming announces commitment to build a new downstream manufacturing facility for RUCONEST®

November 19, 2020 at 12:00 AM EST
Pharming Group announces it has committed to building a new facility to expand the Company’s downstream processing capacity for its lead product, RUCONEST® (recombinant C1 esterase inhibitor (rhC1INH)).